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http://www.trialsjournal.com/content/14/1/431STUDY PROTOCOL Open AccessThe use of mindfulness-based cognitive therapy
for improving quality of life for inflammatory
bowel disease patients: study protocol for a pilot
randomised controlled trial with embedded
process evaluation
Mariyana Schoultz1*, Iain M Atherton1, Gill Hubbard1 and Angus JM Watson1,2Abstract
Background: Inflammatory bowel disease (IBD) is a chronic condition with an unpredictable disease course. Rates
of anxiety and depression among IBD patients in relapse (active disease symptoms) as well as in remission are
higher than in the general population. Previous studies suggest that the prolonged effect of pain, anxiety, distress
and depression have a detrimental effect on patients’quality of life (QoL). Poor QoL in itself is associated with
further symptom relapse. Mindfulness based cognitive therapy (MBCT) is a psychological group intervention that
has the potential to improve QoL. When used in other chronic conditions, it demonstrated reduced negative effect
from pain and psychological factors at completion of an 8-week MBCT course. The effect of MBCT has never been
researched in IBD. The aim of this study is to obtain the information required to design a full scale randomised
controlled trial (RCT) that will examine the effectiveness of MBCT in improving quality of life for IBD patients.
Methods/Design: This is an exploratory RCT with embedded process evaluation. Forty IBD patients will be recruited
from NHS outpatient gastroenterology clinics and will be randomised to either a MBCT (intervention) group or to a
wait-list (control) group. All participants will undergo 16 h of structured group training over an 8-week period, with the
control group starting 6 months later than the intervention group. Primary outcomes are recruitment, completion/
retention rates and adherence and adaptation to the MBCT manual for IBD patients. The secondary outcome is to
assess the feasibility of collecting reliable and valid data on proposed outcome measures such as quality of life, anxiety,
depression, disease activity and mindful awareness. The process evaluation will use a survey and focus groups to assess
the acceptability of the intervention and trial procedures for IBD patients.
Discussion: The outcomes of this study will help define the barriers, uptake and perceived benefits of MBCT program
for IBD patients. This information will enable the design of a full-scale study assessing the effect of MBCT on quality of
life for IBD patients.
Trial registration: Current Controlled Trials: ISRCTN27934462
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Inflammatory bowel disease (IBD) is a group of relapsing
chronic gastrointestinal conditions characterised by in-
flammation of the gut [1,2]. The condition affects the
normal function of the gastrointestinal system, resulting
in symptoms such as bloody diarrhoea, vomiting, severe
pain and malnutrition [3,4]. It affects approximately
250,000 people in the UK and 28 million worldwide with
its incidence rising [5,6]. The two main types are Crohn’s
disease (CD) and ulcerative colitis (UC). While there is a
concern about the increased risk of colorectal cancer
in IBD patients [7], the main burden for patients is the
relapsing course of the disease and its detrimental impact
on psychosocial functioning and quality of life [8].
Anxiety, depression and quality of life in IBD
Anxiety and depression rates among IBD patients are
higher than in the general population even in remission
(when symptoms are settled) [9,10]. Previous studies
have suggested that the prolonged effect of pain, anxiety,
distress and depression have detrimental effects on qual-
ity of life (QoL) [11]. Poor QoL is further associated with
symptoms relapse and additional clinical difficulties such
as tissue inflammation [12,13]. Anxiety, depression and
relapse thus links together in a self-perpetuating cycle
with pernicious implications for those affected.
Use of medication for management of anxiety, depression
and pain and its limitations
Evidence suggests that the use of antidepressants can
have a positive effect on QoL and symptom management
for IBD patients by reducing anxiety and depression
[14-16]. This is encouraging. However, some patients using
antidepressants have reported unpleasant side effects while
others have reported that the antidepressants have no
effect on their low mood or anxiety [17-19].
The use of painkillers for pain management also has
its limitations. There are subgroups of IBD patients who
irrespective of using anti-inflammatory and pain medica-
tion continue to suffer severe discomfort, again with a
knock-on effect and making symptom exacerbation more
likely [20].
In addition, poor medication compliance is frequently
reported among IBD patients, with up to 40% of patients
regularly omitting their prescribed medications [21,22].
Pharmacology is thus very limited. The search for alter-
native evidence-based approaches is a pressing concern.
Mindfulness based cognitive therapy
Mindfulness based cognitive therapy (MBCT) is a non-
pharmacological psychological group program designed
by Segal et al. [23]. The MBCT program is largely based
on the mindfulness-based stress reduction (MBSR) pro-
gram developed by Jon Kabat- Zinn for coping withstress and chronic illness [24]. Both programs involve
teaching individuals various stress management, relax-
ation, self-care and self-help techniques in a systematic
way over an 8-week period. In both, the core skill taught
is mindfulness, which uses meditation practice to in-
crease attention and awareness [25]. The working defin-
ition of mindfulness in the program is: ‘The awareness
that emerges through paying attention on purpose, in
the present moment, and nonjudgmentally to the unfold-
ing of experience moment by moment’ [26]. The main
difference to the MBSR program is that MBCT has com-
bined cognitive therapy exercises with the mindfulness
skill. This combination is believed to further enable
patients to increase their awareness and facilitate early rec-
ognition of any recurring unhelpful thinking patterns
often associated with depressive symptoms and anxiety
[23]. Hence, the National Institute for Health and Care
Excellence guidelines makes a recommendation for the
use of MBCT program as a psychological intervention in
the ‘clinical management of persistent sub threshold de-
pressive symptoms or mild, moderate or severe depression
in adults (including people with a chronic physical health
problem)’ [27].
Although the exact mechanism of how mindfulness-
based interventions work is not yet fully understood, the
evidence so far suggests that at program completion,
participants would experience reduced negative effects
from pain, distress, anxiety and depressive symptoms.
For example, a systematic review and a meta-analysis of
the effectiveness of mindfulness-based interventions on
anxiety, depression and psychological distress in patients
with chronic pain conditions [28] and chronic medical
conditions [29] such as fibromyalgia, cardiac and cancer
patients, have shown positive effect on anxiety, depres-
sion and psychological distress.
An observational study examining the relationship
between mindfulness, QoL, depression and anxiety in
patients with ulcerative colitis found a positive association
between increasing mindfulness and reducing depression
and anxiety [30]. However, MBCT and its effect on QoL
has never been researched in a RCT with both Crohn’s and
ulcerative colitis patients.
Thus, the MBCT program may be the therapy that
can provide a relief from the negative effects of a lifelong
management of the disease for IBD patients.
Hypothesis
The hypothesis is that MBCT will improve QoL scores
for IBD patients as well as improve anxiety and depres-
sive symptom scores. This hypothesis is based on
previous studies using mindfulness based programs in
other chronic condition populations. Hence, the pro-
posed pilot study is the first step towards testing the hy-
pothesis in a definitive RCT and gathering the necessary
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the usefulness of MBCT for IBD patients.
Aims and objectives
The overall aim of this study is to pilot the MBCT program
with IBD patients in a RCT and examine the feasibility of
running a large RCT testing the above hypothesis.
The specific objectives of the pilot are:
1. To determine the feasibility of conducting a
large-scale RCT of group MBCT for improvement
of IBD QoL.
2. To adapt the intervention manual devised by Segal
et al. [31], outlining how to carry out an MBCT
program for IBD patients.
3. To use data arising from differences between MBCT
and control arm to inform a power calculation for
sample size of a definitive RCT.
4. Estimate trial eligibility, recruitment (percentage of
IBD patients who consent to the trial) and completion/
retention rates (percentage of participants completing
the trial).
5. To embed a process evaluation within the pilot trial
to assess the acceptability of the intervention and
trial procedures for IBD patients, such as:
a. Acceptability of recruitment, randomisation and
consent procedure
b. Acceptability and feasibility of collecting reliable
and valid data on primary and secondary
outcomes (including follow-up at 6 months)
c. Fidelity of intervention.
d. Acceptability of length of intervention
e. Appropriateness/suitability of the intervention
used
f. Barriers to attendance
g. Expectations about intervention
h. Perceived impact on QoLMethods and design
Design
This exploratory trial is designed in two phases. Phase 1
is a two-arm pilot RCT (MBCT treatment vs. wait-list
control group) with three assessments (baseline, post
treatment and 6 months). Phase 1 will assess eligibility,
uptake, drop-out rates and sample size calculation as
well as adaptation and adherence to MBCT manual.
This design is consistent with similar studies where a
non-pharmacological intervention is investigated in IBD
population [32-38].
Phase 2 is a process evaluation assessing the feasibility
and acceptability of the intervention, primary and sec-
ondary outcomes and trial procedures as well as barriers
to attendance and perceived benefits to patients. This
design is in line with the Medical Research Council (MRC)framework for the development and evaluation of complex
interventions to ensure that both the intervention and trial
procedures are optimised and can be incorporated into
routine clinical practice [39].
Setting and recruitment
The study will take place across two health board areas
in the north of Scotland, an area comprising of approxi-
mately 800,000 people living across a large geograph-
ical area including urban and remote rural locations.
Recruitment will focus on gastroenterology outpatient
clinics.
Phase 1 - Pilot RCT
Participant selection
Less than one-third of RCTs recruit to proposed number
[40]. Assessing recruitment is a key component of this
study. Ensuring an effective recruitment strategy is thus
important. Accordingly, the recruitment strategy devised
in this study draws on best evidence [41] tailored to the
specific requirements of people with IBD. Specific as-
pects of the recruitment strategy were developed in col-
laboration with all parties involved in the care of IBD
patients, namely specialist IBD nurse, gastroenterology
clinicians and research nurses.
Clinical staff at participating gastroenterology out-
patient clinics will identify people who meet the study’s
inclusion criteria. They will approach consecutive pa-
tients in clinics or by sending an invitation letter with
study information and research team contact details. In-
terested participants will then contact the researcher by
telephone or email to register interest. A screening visit
with the researcher will then be arranged. Informed writ-
ten consent will be obtained at the first visit by a mem-
ber of the research team.
Inclusion criteria
1. Be able to verbally communicate and write in English
(English does not have to be their first language).
2. Able to give informed consent.
3. Age of 18 years or over (no upper limit).
4. Confirmed diagnosis of Crohn’s disease or ulcerative
colitis (by clinician).
5. Ability to do light exercise (for example, to lift arms
above the head or bend knees) because part of the
practices in the program require this movement.
6. Able to commit to attend the eight sessions
(participants should consider their personal
circumstances to assess if this is practical and
feasible for them).
7. To be able to commit to do home practice of up to
45 minutes daily over the 8 weeks of the study (this
is a core component of the program).
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the last 3 months. Any change of antidepressants
within the last 3 months might interfere with the
program.
9. Participants will have to be in remission of
symptoms.
Exclusion criteria
Anyone not meeting the above criteria by definition will
be excluded from the study. In addition, the following
exclusion criteria will apply:
1. Major psychiatric illness. The treatment for a major
psychiatric illness may interfere with the program.
2. Active alcohol or drug dependency. Any alcohol or
drug dependency may interfere with the program.
3. Scheduled for major surgery in the next 3 months.
Any scheduled surgery within the next 3 months
will interfere with the program schedule.
4. Participation in a pharmacological study or
psychological intervention study within the last
6 months or intention to participate in a
pharmacological study during the duration of this
study. Both will interfere with the program.
5. Have recently (within the last 3 months) been
prescribed antidepressants. Any change of
antidepressant in the last 3 months may interfere
with the program.
6. With exacerbated symptoms (acute phase). Having
exacerbated symptoms will make it very difficult for
participants to attend the two hourly sessions or to
commit to the home practice. This could cause
extra unwanted stress for the patient.
Randomisation
Randomisation will be performed using a dedicated soft-
ware solution after participants have given written con-
sent and baseline data have been collected. Group
allocation will be to ‘MBCT group’ or ‘wait-list control
group’ in a 1:1 ratio. To ensure similarity between the
groups, randomisation will take account of gender and
type of disease. The randomisation will be carried out by
an independent statistician.
Minimising bias
Participants will self-complete all the questionnaires.
Data entry will be done by the lead researcher and inde-
pendently checked by a second person. Data analysis will
be done by two researchers independently and differ-
ences will be rectified by a third person.
MBCT intervention
The MBCT program used in this study will follow the
manual developed by Segal et al. [31]. In brief, themanual proposes the following format for the eight
group sessions:
 Welcome and introduction to the session theme
 A short opening meditation
 A discussion of at-home practice
 An introduction and practice of new exercises
 A group reflection/discussion
 A review of the next weeks’ at-home practice
 A closing sitting meditation
A sample list of activities for session 1 is presented
below. The manual also suggests for an additional full
day of mindful practice to take place between weeks 6
and 7 (usually on a weekend). In the full day of practice
participants will go through all the learned meditations
one after another in silence, with the group reflection
and discussion taking place at the end of the practice
day. An example schedule for a day of mindful practice
is presented below. Due to resource constraint, in this
study, the full day of practice will be offered to partici-
pants after they have completed the 8-week course.
A sample list of activities for session 1
Theme: Awareness and automatic pilot
1. Establish the orientation of the class
2. Set ground rules regarding confidentiality and
privacy
3. Ask participants to pair up and introduce
themselves to each other than to the group as a
whole, giving their first names and if they wish,
saying what they hope to get out of the program
4. The raisin exercise
5. Feedback and discussion of the raisin exercise
6. Body scan practice-starting with short breath focus
7. Feedback and discussion of body scan
8. Home practice assignment: Body scan for 6 out of 7 days
 Mindfulness of a routine activity
 Distribute audio files: cd’s for those that not have
email and session 1 participant hand-outs.
9. Discuss in pairs:
 Timing for home practice
 What obstacles may arise
 How to deal with them
10. End the class with a short 2–3 minute focus on the
breath.
Example schedule for a day of mindful practice [35]
9.45-10.00 Arrival
10.00-10.05 Sit in silence
10.05-10.20 Welcome, introduction, ground rules
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thoughts and choiceless awareness
10.50-11.30 Mindful stretching
11.30-12.00 Body scan
12.00-12.05 Instruction for lunchtime: bringing focus on
awareness of eating, tasting, chewing,
swallowing, slowing down
12.05-13.05 Lunch followed by mindful walk
13.05-13.20 Sitting meditation
13.20-13.50 Walking meditation
13.50-14.20 Mountain meditation
14.20-14.40 Mindful stretching
14.40-15.00 Silent sit or extended breathing space
15.00-15.30 Feeding back experience of day in pairs
15.50-16.30 Large group discussion and close
The program will be delivered by two experienced
MBCT practitioners that have been briefed on the key
concerns and difficulties that IBD patients experience as
well as the nature of the disease. An experienced practi-
tioner will have completed an 8-week MBCT course and
maintained a personal practice for at least 1 year. In
addition they will have facilitated at least one 8-week
MBCT program.
Participants will be encouraged to do daily home prac-
tice for the duration of the program and keep a home
practice diary. Participants will be provided with guided
practice CDs and hand-outs with a written summary for
each session and instruction for home practice. Each
weekly session will be approximately 120 minutes and
will be audio recorded.
Wait-list control
The control group will continue to receive their standard
care and in addition will receive a leaflet entitled ‘Staying
well with IBD’. The leaflet is readily available to download
from the Crohn’s and Colitis UK website, but participants
in the study will receive a printed copy [42]. After 6 months
follow-up data are collected; the wait-list group will have
an opportunity to attend a MBCT program if they wish.
Data collection
A screening and recruitment log will be completed by a
researcher to document all patients considered for the
study and subsequently included or excluded at each
stage of the recruitment process with reasons given. This
log will include information such as date when informa-
tion was given about the study, and date of recruitment
and randomisation. The data will inform the estimate
for recruitment rates for a full trial and address aims 1
and 4. A full consort diagram of subject flow is pre-
sented in Figure 1.
At baseline, demographic information including age,
gender, education, income and marital status will berecorded, to allow the success of randomisation to be
assessed [43].
The MBCT practitioners will complete an attend-
ance log to document the number of practice sessions
attended by each participant. This log will inform the
estimated attrition rates for a full trial and will address
aim 3.
Semi-structured interviews with the practitioners de-
livering the MBCT intervention will be conducted to
find out if any changes to the manual should be done to
accommodate the needs of this patient group. This will
address aim 2.
Outcomes and assessments
The outcomes for this study are consistent with relevant
published studies assessing the use of mindfulness-based
program in populations with chronic health problems
[44] as well as with studies investigating the effects of
non-pharmacological programs on QoL in IBD patients
[35,36,45]. They include assessment of disease specific
QoL, mood, mindful awareness, disease activity and
demographics. All assessment tools used in the trial are
validated and reliable. All outcomes will be assessed at
baseline, post treatment and 6 months.
Proposed primary outcome
Quality of life All participants will be required to
complete the disease specific IBD quality of life (IBDQoL)
questionnaire consisting of 32 questions. The question-
naire has four domains, including bowel symptoms, sys-
temic symptoms, emotional factors and social factors.
Within the questionnaire, participants will rate their
symptom experience over the previous 2 weeks. Low
scores indicate more severe disease activity and/or higher
emotional and social dysfunction. A relatively good correl-
ation between the IBDQoL and a widely used measure of
disease activity, the Crohn’s Disease Activity Index is re-
ported (r = −0.67; P <0.001) [46,47].
Proposed secondary outcomes
Anxiety Anxiety will be measured by the State and Trait
Anxiety Inventory (STAI) Y1 and Y2 form, consisting of
40 questions on a self-report basis. The inventory mea-
sures two types of anxiety: anxiety related to an event
and anxiety level as a personal characteristic. Higher
scores are positively correlated with higher levels of anx-
iety [48]. This tool is widely used to measure anxiety
and regarded as highly reliable [13].
Depression Low mood and depression symptoms will be
measured with the Beck’s depression inventory (BDI-II),
consisting of 21 group of statements referring to the last
2 weeks. Each answer is being scored on a scale value of 0
to 3. Higher total scores indicate more severe depressive
Figure 1 Consort diagram describing flow of patients through study.
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sistency of the BDI-II is high [49,50].
Disease activity Disease activity will be measured with
the eight-item questionnaire Crohn’s Disease Activity
Index (CDAI) for Crohn’s patients [51,52] and six-item
questionnaire Simple Clinical Colitis Activity Index
(SCCAI) for ulcerative colitis patients [53]. Both tools are
widely used to measure disease activity with IBD patients.
Mindful attention Mindful attention will be measured
with the 15-item scale Mindful Attention Awareness
Scale (MAAS). This scale consists of collection of state-
ments about everyday experiences graded by partici-
pants, using a scale of 1 to 6 which indicates how often
each experience occurs. Higher scores reflect higher
levels of dispositional mindfulness. The validation of this
tool has been examined in a series of studies indicating
strong psychometric properties and validity [54,55].
Phase 2 - Process evaluation
To address aim 5 and examine the implementation
and receipt of the intervention and trial procedures,
a detailed process evaluation will be undertaken. Thisevaluation process will assess the acceptability of recruit-
ment, randomisation and consent procedure for patients,
acceptability and feasibility of collecting reliable and valid
data on primary and secondary outcomes, fidelity of
protocol, acceptability of length of intervention for
patients, appropriateness/suitability of the intervention
used, barriers to attendance, expectations about interven-
tion and perceived impact on QoL.
Observations of MBCT training sessions will be
undertaken by audio recording of all sessions to assess if
specific components of the protocol are delivered and to
use the qualitative data to assess the appropriateness of
the intervention used. These data will address aim 5c.
All participants will be asked to self-complete a postal
survey asking their views on research procedures such
as consent and randomisation procedures and reliability
of questionnaires. The MBCT group will answer further
questions on expectations, acceptability, appropriateness
and perceived impact of the intervention as well as the
length of the program. These data will address aims 5a,
5e, 5f, 5g and 5h.
A post-intervention focus group will be facilitated to
further explore the participants’ views and experiences
of the MBCT program and trial procedures, using the
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recorded. A list of topic guides for the focus group is
presented below.
List of topic guides for the focus groups
Expectations
1. Did you have any expectations regarding the self-help
program?
2. If yes, what were they?
3. Were your expectations met/ unmet in any way?
And How?
Length and difficulty of program
4. Was the length of eight weeks for the program
acceptable?
5. Did you find the program difficult to follow?
6. Please tell us which specific parts of the program
you found difficult to follow.
Potential benefits
7. Do you think this program has brought any benefit
to you?
8. Please tell us how you think the program benefited
you.
9. Do you think you will continue to use some of the
techniques you learned in the program?
Recruitment and randomisation
10. Do you think the process of recruitment was
acceptable?
11. Do you think the patient information sheet was
easy to understand?
12. Any suggestions to make it clearer to understand
13. Did you feel comfortable with the process of consent
and randomisation?
Questionnaires
14. Was filling the questionnaires at the start and at the
end of the eight weeks too much of a burden?
15. Can you please tell us what difficulties you came
across with the questionnaires and perhaps any
suggestions of how to overcome those difficulties
Barriers to attending
16. Were there any barriers to attending the program?
17. Can you please tell us what you think were barriers
to attendance?
What did you enjoy?
18. Did you enjoy the program?
19. Which parts did you most enjoy?
Availability of MBCT program
20. Do you think this program should be made available
to IBD patients through NHS?
Ethical and research and development approval
A favourable ethical opinion was obtained from NRES
Committee for North of Scotland on 8th April 2013 (REC
ref 13/NF/0018). NHS Highland and NHS Grampian R&DManagement Approval was obtained on 9 April 2013 and
14 September 2013, respectively.
Sample size
The nature of this study is a pilot RCT. Thus, a formal
sample size calculation was not performed. The deter-
mined sample size of n = 40 was calculated based on the
estimated number of participants expected to complete
the 8-week program.
This number was achieved by the following calcula-
tion. Recommendation for pilot sample size calculation
is 30 [56,57]. Literature suggest that attrition rate of ap-
proximately 25% is to be reasonably expected in mind-
fulness intervention studies [58]. A sample size of 40
with a 25% attrition rate will give an estimated sample of
30 subjects completing the 8-week program.
The approximate number of IBD patients is 600 in
NHS Highland and 1,741 at NHS Grampian. With esti-
mated recruitment rates of IBD interventional studies
ranging between 10% and 20% (234 to 468 between the
two sides), a sample size of 40 is reasonably achievable.
Analysis
Audio-recorded focus groups and interviews with practi-
tioners will be transcribed verbatim. Transcripts will be
analysed thematically using the framework analysis ap-
proach [59] which is a rigorous method that allows themes
to be identified (and organised) within the groups or be-
tween the groups. Hence, notable differences in experi-
ences and perceptions can be identified.
From quantitative data we will generate the following:
estimates of eligibility, recruitment and retention rates,
speed of recruitment, and completion rates of study as-
sessment tools (objectives 1 and 4); Descriptive presenta-
tions of the proposed primary and secondary outcomes
will be made to inform a sample size calculation for a
large-scale trial and decisions as to whether their inclu-
sion would be informative in a future trial (objective 3).
Discussion
There is increasing evidence that mindfulness-based in-
terventions can provide benefits to people with chronic
ill health in terms of improving QoL and reducing anx-
iety and depressive symptoms. However, the use of these
interventions in patients with both CD and UC is not
researched. This paper outlines a protocol for a pilot
RCT with embedded process evaluation that aims to
provide data on eligibility, uptake and retention rates,
barriers to recruitment and attendance and perceived
benefit to IBD patients. This information is required to de-
sign a full-scale RCT assessing the effectiveness of MBCT
on QoL for IBD patients.
This study is the first RCT to examine the use of
MBCT in patients with IBD. The study design is a
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feasibility and acceptability of the intervention in patients
with IBD. The 6-month follow-up data will give an indica-
tion as to how long (if any) benefit from the intervention
would last. The type of information that will be collected
from the evaluation process will give an insight into im-
portant questions such as participants’ subjective thoughts
and experiences about the intervention (expectations,
potential benefits, barriers to attending and availability of
the program through NHS) as well as their feedback on
recruitment process and procedures.
In addition, the results of this project will provide im-
portant information on integration of mindfulness-based
interventions with usual medical care as well as applica-
tion of MBCT for IBD.
Trial status
Recruitment commenced in May2013 and is ongoing.
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